Why Castle Biosciences’ Rally Might Just Be Getting Started

Castle Biosciences (NASDAQ:CSTL) rallied more than 20% after delivering a strong Q3 performance. When analyzed through the lens of the Adhishthana Principles, the stock shows clear signs of momentum building. Here's why the current setup looks promising and what lies ahead.

Read the full article on Benzinga for deeper insights into the Adhishthana Cycle, the stock’s recent trajectory, and expert commentary.